Dispatches from a Pandemic: Here’s how a COVID-19 vaccine could make its way into wealthier Americans’ arms first

This post was originally published on this site

Economists hold that a good is most efficiently allocated when it goes to the people who value it the most and hence are willing to pay the most for it. 

It’s for that very reason that bioethicists and infectious disease doctors worry that initial doses of a coronavirus vaccine, once approved for Emergency Authorization Use, will make its way into the arms of wealthier Americans first.

An independent group of medical experts voted Thursday in favor of the Food and Drug Administration granting EUA approval for BioNTech BNTX, -1.51% and Pfizer Inc.’s PFE, -1.49% vaccine candidate. (A similar meeting for Moderna’s MRNA, +1.98% vaccine candidate is scheduled for Dec. 17.)

Health-care workers and nursing-home residents should be the first to get vaccinated, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices recommended on Dec. 1. 

States aren’t required to follow the committee’s recommendations, but health experts are urging state governors to stick to ACIP’s recommendations going forward because it gives them a science-based framework to follow that can ultimately help end the pandemic more efficiently.

That being said, wealthy Americans who are accustomed to flying in private jets and can afford to pay steep annual fees for personalized care through medical concierge practices aren’t too keen on waiting in line for a vaccine.

Patients at elite medical concierge practices are calling and texting ‘all day long’ asking when they can get the vaccine

Dr. Ehsan Ali of Beverly Hills Concierge Doctor Inc, said he has been receiving phone calls and texts from patients “all day long” inquiring about when they can get the vaccine. His practice, unlike many other medical concierge practices, accepts some insurance plans.  

Andrew Olanow, co-founder of Sollis Health concierge service, which serves patients in Beverly Hills, Manhattan and the Hamptons, said he started fielding questions from patients on when they can get a coronavirus vaccine as soon as the pandemic took off in early March. 

His practice charges adults under the age of 45 $3,000 a year plus $2,000 a year for each additional adult. For people above 45 years old, the membership fees start at $5,000/year plus $3,000 for each additional adult above 45.

“The initial questions were when and will there be a vaccine?” Olanow said. “Then once you started seeing trial data become available, particularly from Pfizer, that’s when we started getting much more pointed questions from patients saying ‘When specifically is that vaccine going to be available?’”

‘The initial questions were when and will there be a vaccine? Then once you started seeing trial data become available, particularly from Pfizer, that’s when we started getting much more pointed questions from patients saying ‘When specifically is that vaccine going to be available?’

— Andrew Olanow, co-founder of Sollis Health concierge service

He tends to respond to these types of questions by assuring patients that he and his staff are taking all the appropriate steps now, for instance, procuring ultra-low temperature freezers to store the Pfizer vaccine, so that if/when it’s approved, Sollis Health be ready to get its patients vaccinated. 

Don’t miss: The perils of transporting millions of COVID-19 vaccines with dry ice across the U.S.

“We’ll be working hard to get access to the vaccine for the members of our practice when it becomes available to a certain risk profile,” Olanow told MarketWatch. “My guess is that we as members of the private sector will be able to move quicker than the public sector.”

How wealthy Americans may get vaccinated earlier than lower-income families

Ideally, the distribution of a coronavirus vaccine would follow the same principles and framework that informs organ donation registries, said Govind Persad, a professor of health law and bioethics at the University of Denver.

“At the highest line, in transplantation we seek to balance two sets of concepts, generally referred to as ‘medical utility’ and ‘justice’,” said Joel Newman, who has served as a staff liaison on the ethics committee at the United Network for Organ Sharing (UNOS), a private nonprofit organization that manages the nation’s organ transplant system under contract with the federal government.

Justice, he said, refers to fairness, while medical utility refers to “all the evidence-based criteria that we know would point to good treatment outcome.”

If who receives an organ transplant were only determined by medical utility, that could ‘mean that we treat more people who may be relatively healthy and who haven’t been waiting as long, at the expense of people who might die soon and those who have already waited a long time because they’re hard to match.’

“The key, in our experience, is to strike a balance between these factors. They often compete, and to go to one extreme or another is probably not the best for everyone.”

If medical utility was the only factor determining who receives an organ transplant , that could “mean that we treat more people who may be relatively healthy and who haven’t been waiting as long, at the expense of people who might die soon and those who have already waited a long time because they’re hard to match,” he said.

In contrast, “over-emphasizing justice would mean that we treat many very sick patients, but many may die soon afterward or need a repeat transplant, thus removing the chance for better-matching people to get a successful transplant.”

To overcome these challenges, UNOS relies on a computerized matching system that scores an individual and takes into account other factors including the location of the donor and blood type.

What’s never taken into account is an individual’s financial or social status, Newman, a senior spokesman for UNOS, told MarketWatch. Not only would that be illegal, but it would also go against UNOS’ ethical code of conduct. 

That said, wealthier people who may require an organ transplant are more likely to expedite the waiting process compared to lower-income people, Persad said. 

Affluent patients can sometimes do this by getting on multiple organ waitlists in multiple facilities or states, traveling to a foreign country, or convincing a doctor to “misstate exactly how at risk somebody is to move them up in line.”

Well-resourced Americans could potentially use those same strategies to receive some of the earliest doses of a coronavirus vaccine, said Persad, who co-wrote a paper titled “Fairly Prioritizing Groups for Access to COVID-19 Vaccines” with Dr. Ezekiel Emanuel, a member of President-elect Joe Biden’s coronavirus task force and Dr. Monica Peek, a medical professor at the University of Chicago. 

For instance, because different states likely will follow different allocation models after health care workers and long-term care residents are inoculated, it could create an opportunity for arbitrage “where they’ll go where they think they have the best chance.”

Having some kind of residency requirement could make “shopping around” more difficult, he added, but ultimately there needs to be vaccine allocation criteria “that health care providers internalize as an ethical obligation.”

“Ideally you’d also want to have one that makes sense to people — so not ones that people are like ‘Look, this is ridiculous I should go around it,’ kind of like some of the coronavirus restrictions where people have gone around them because they didn’t seem to make sense.”

When it comes to college admissions — another area where the wealthy can have an upper hand, for various reasons — one could make the case that an upper-income family donating money to boost their child’s chances of getting accepted indirectly benefits other students by potentially adding funds to scholarship programs, Persad said.

“That likely is not true for COVID-19 vaccines because there are hard short and medium-term manufacturing constraints — rich people paying Pfizer or some other supply chain actor more won’t make more vaccines available.”

Add Comment